mole (structure)

mole (structure)
Name	Mole (structure)
Latin	Nevus
System	Integumentary

mole (structure)

A mole (structure) is a localized skin lesion composed of nevomelanocytic or nonmelanocytic cell proliferations commonly present on the integument. Moles vary in color, size, and shape and are evaluated in clinical contexts alongside conditions managed by dermatologists, oncologists, and pathologists. Assessment often involves tools and guidelines from organizations such as the World Health Organization, American Academy of Dermatology, and standards influenced by research from institutions like Mayo Clinic, Johns Hopkins Hospital, and Memorial Sloan Kettering Cancer Center.

Definition and Overview

The lesion termed mole is defined in dermatologic nomenclature and classification systems developed by bodies including the World Health Organization, the International Agency for Research on Cancer, and specialist societies such as the European Academy of Dermatology and Venereology. Consensus statements from panels at conferences like the American Society of Clinical Oncology meetings and textbooks from publishers such as Elsevier and Springer describe moles as clonal proliferations arising within the epidermis, dermis, or both. Clinical algorithms taught in residency programs at institutions like Harvard Medical School and Stanford School of Medicine guide differentiation of benign moles from neoplasms considered by authorities such as National Comprehensive Cancer Network.

Anatomy and Histology

Anatomically, moles involve components of the skin layers characterized in histology atlases by contributors affiliated with Johns Hopkins University, University of Oxford, and University of Cambridge. Histologic patterns include junctional, compound, and intradermal arrangements defined in classifications endorsed by the World Health Organization. Cellular constituents—melanocytes, keratinocytes, and dermal fibroblasts—are described in resources from laboratories at National Institutes of Health, Sloan Kettering Institute, and Cold Spring Harbor Laboratory. Immunohistochemical markers such as S100, HMB-45, and Melan-A are detailed in pathology protocols from centers like Mayo Clinic and Cleveland Clinic.

Types and Classification

Clinical and histologic subtypes are enumerated by dermatology references used in curricula at University of California, San Francisco, University College London, and Karolinska Institutet. Common categories include congenital nevi, acquired common nevi, dysplastic (atypical) nevi, and special-site nevi as noted in guidelines from the British Association of Dermatologists and reviews in journals like The Lancet and New England Journal of Medicine. Classification systems incorporate terminology from the International Classification of Diseases and staging frameworks that interface with oncology recommendations from the American Joint Committee on Cancer.

Causes and Pathophysiology

Pathogenetic mechanisms integrate findings from molecular studies published by teams at Dana-Farber Cancer Institute, Broad Institute, and Salk Institute for Biological Studies. Genetic drivers implicated include mutations in genes discussed in reports originating from National Cancer Institute, with pathways involving MAPK signaling highlighted in symposia at Cold Spring Harbor Laboratory and articles in Nature. Environmental modifiers such as ultraviolet exposure are examined in epidemiologic studies from World Health Organization collaborations and public health analyses by Centers for Disease Control and Prevention.

Clinical Evaluation and Diagnosis

Diagnostic approaches utilize clinical inspection protocols taught at Mayo Clinic, dermoscopic criteria from research groups at Erasmus University Medical Center, and biopsy standards established in pathology textbooks by editors at Oxford University Press. Differential diagnosis references include distinctions from lesions reviewed by specialists at Memorial Sloan Kettering Cancer Center and criteria from consensus panels convened by the American Academy of Dermatology and European Society for Medical Oncology. Adjunctive technologies such as reflectance confocal microscopy and mole-mapping systems are described in device assessments from Food and Drug Administration filings and trials at Massachusetts General Hospital.

Management and Treatment

Management strategies reflect recommendations from clinical practice guidelines by organizations like the National Comprehensive Cancer Network, the American Academy of Dermatology, and surgical protocols taught at Johns Hopkins Hospital and Mayo Clinic. Options range from conservative observation endorsed in consensus statements to excisional procedures following standards from the Royal College of Surgeons and reconstructive techniques discussed in literature from American Society of Plastic Surgeons. When malignant transformation is suspected, treatment pathways align with oncology protocols from National Cancer Institute and multidisciplinary tumor boards at comprehensive centers such as Memorial Sloan Kettering Cancer Center.

Epidemiology and Prognosis

Epidemiologic data are published by agencies including the World Health Organization, Centers for Disease Control and Prevention, and national cancer registries like the Surveillance, Epidemiology, and End Results Program which inform population-level prevalence and risk assessments. Prognosis for benign lesions is generally excellent as summarized in reviews from New England Journal of Medicine and long-term cohort studies from institutions such as Karolinska Institutet and University of Melbourne. Risk stratification frameworks are integrated into public health guidance by entities like the American Cancer Society.

Category:Skin lesions